Advancements In Vitiligo Treatments And Global Expansion Will Drive Future Success

Shared on01 May 25
Fair value Increased 1.23%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 12%

AnalystConsensusTarget has decreased revenue growth from 25.2% to 9.5%, decreased profit margin from 43.2% to 38.0% and increased future PE multiple from 21.3x to 32.0x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 8.05%

AnalystConsensusTarget has increased revenue growth from 18.6% to 25.2% and decreased future PE multiple from 25.9x to 21.2x.